Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell Immunotherapy

BACKGROUND: EBV type II latency tumors such as Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL) and nasopharyngeal carcinoma (NPC) express a limited array of EBV antigens including Epstein-Barr nuclear antigen (EBNA)1, latent membrane protein (LMP)1, LMP2, and BamH1-A right frame 1 (BARF1). Adoptiv...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cytotherapy
Auteurs principaux: Kalra, Mamta, Gerdemann, Ulrike, Luu, Jessica D, Ngo, Minthran C, Leen, Ann M, Louis, Chrystal U, Rooney, Cliona M, Gottschalk, Stephen
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435433/
https://ncbi.nlm.nih.gov/pubmed/30396848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2018.08.001
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires